Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 14858 pages

Showing 1 - 50


Putting the Patient at the Center: The Career of Jeffery Ward, MD, FASCO

Editor’s Note: ASCO was deeply saddened by the news that Dr. Jeff Ward passed away on November 3, 2022. In an interview with Dr. Ward this past summer, published in ASCO Connection (August 30, 2022), ASCO recognized Dr. Ward’s commitment to exceptional patient care and public advocacy. An...

prostate cancer
genomics/genetics

I Have the BRCA2 Gene Mutation: Here’s What I’m Doing to Prevent Cancer

My father was diagnosed with prostate cancer in 1994, when he was just 55 years old. He died 6 years later. The cancer was so aggressive, it took only a few weeks from the time he was diagnosed for the cancer to grow to the size of a softball, and even a radical prostatectomy couldn’t save his...

hepatobiliary cancer

Experimental Drug Under Study in Liver Cancer

A new drug that inhibits an enzyme playing a crucial role in cell division and growth has shown signs of anticancer activity with manageable side effects in patients with liver cancer who have been treated unsuccessfully previously with up to three lines of treatment. These findings were presented...

solid tumors

AKT Inhibitor Shows Signs of Activity in a Trial Matching Drugs to Tumor Gene Mutations

In a trial matching the genetic makeup of tumors with new treatments, tumors shrank in 22% of patients with cancer who received the AKT inhibitor ipatasertib. Participants included those with breast cancer and endometrial cancer as well as those with two rarer types of cancer, anal and salivary...

hematologic malignancies

Liquid Biopsies May Identify Patients With Cancer at Higher Risk of Developing Additional Blood Cancers

Researchers have found that liquid biopsies may be able to detect the blood disorder clonal hematopoiesis, which places patients at higher risk of developing blood cancers. The findings were presented at the 2022 European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer...

Education and Diligence Required to Confront the Challenges of Pregnancy-Associated Breast Cancer

Physiologic changes of pregnancy, such as increased breast volume and firmness, present challenges to detecting breast cancer. Meeting those challenges requires “education and continued diligence, both on the patient side as well as on the physician side,” Luis Zabala Blanco, Jr, MD, said in an...

breast cancer

Pregnancy Confers ‘Dual Effect’ on Breast Cancer Risk

“Pregnancy confers a dual effect” on breast cancer risk, “with an initial transient increased risk for breast cancer that is followed by long-term protection over time,” Luis Zabala Blanco, Jr, MD, noted in an update on the pathology of pregnancy-associated breast cancer, which was presented at the ...

Heartbreak and a Second Chance at Love and Life

“I knew my husband was dying in June. He’d been living with a terminal diagnosis for 6 years, but suddenly his cancer turned aggressive…. The last time we saw the oncologist, he sent us home with a DNR order and told me to put it on the refrigerator, because that’s where the EMTs look,” writes...

2022 Society for Integrative Oncology Annual International Conference

Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its 2022 Annual International Conference in a hybrid format (virtual and in Scottsdale, Arizona). It was centered on the basic science, education and training, and implementation of integrative oncology in diverse...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Bolivia

The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Bolivia. The aim of this special feature is to highlight the global cancer burden for various countries of the...

breast cancer

Joannie M. Ivory, MD, MSPH, and Lisa A. Carey, MD, on PAM50 Subtype and 21-Gene Recurrence Scores in Younger and Black Women With Breast Cancer

Lisa A. Carey, MD, and Joannie M. Ivory, MD, MSPH, both of the University of North Carolina at Chapel Hill, discuss the higher frequency and treatment implications of nonluminal A or high-risk tumors in Black and younger women. In this study, PAM50 and 21-gene assays revealed different demographic...

breast cancer

Mariana Chavez-MacGregor, MD, MSc, on Adjuvant Endocrine Therapy and Everolimus in HR-Positive, HER2-Negative Breast Cancer

Mariana Chavez-MacGregor, MD, MSc, of The University of Texas MD Anderson Cancer Center, discusses phase III results from the SWOG S1207 trial which was designed to evaluate the role of adjuvant everolimus in combination with adjuvant endocrine therapy among patients with high-risk, hormone­...

National Academy of Medicine Elects 100 New Members

The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...

issues in oncology

The Effect of the Reversal of Roe v Wade on Care of Pregnant Women With Cancer

The repercussions from the decision by the U.S. Supreme Court on June 24, 2022, to overturn Roe v Wade, effectively ending a nearly 50-year federal constitutional right to an abortion and allowing instead states to determine abortion access, are starting to be felt in the cancer care community. The ...

issues in oncology

Legal and Ethical Use of Complementary and Alternative Medicine Interventions in Oncology

In addition to, or instead of, receiving therapies that are the standard of care, patients with cancer sometimes request to receive complementary (therapies used in conjunction with standard cancer treatment) and alternative (nonstandard treatments used in place of standard cancer treatment)...

breast cancer

Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the...

breast cancer

Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx

Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed...

breast cancer

Circulating Tumor Cell Count–Driven Treatment Decisions May Improve Long-Term Outcomes for Patients With Metastatic Breast Cancer

The use of circulating tumor cell counts to guide the choice between chemotherapy and endocrine therapy as first-line treatment for patients with metastatic, estrogen receptor–positive, HER2-negative breast cancer provided overall survival benefits compared with physician’s choice of treatment,...

breast cancer

Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer

The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival compared to fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer, according to results from the phase II SERENA-2 trial presented by Mafalda Oliveira, MD,...

breast cancer

Patients With Breast Cancer Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-Term Recurrence Rates

Patients with breast cancer who paused their endocrine therapy while attempting to conceive experienced short-term rates of breast cancer recurrence similar to patients with breast cancer who did not pause their therapy for pregnancy—and many of them went on to conceive and deliver healthy babies,...

breast cancer

Adding Capivasertib to Fulvestrant May Improve Progression-Free Survival in Patients With Advanced Hormone Receptor–Positive Breast Cancer

In patients with hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitors, the addition of the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant, according to results...

palliative care

How Low-Dose Oral Minoxidil Is Providing Hope for Patients With Later-Stage Alopecia

Chemotherapy-induced hair loss affects 65% of patients with cancer,1 and the psychosocial impact on these patients can be profound; it may include anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being.2 In some instances, the fear of hair loss from...

breast cancer
immunotherapy

Sara A. Hurvitz, MD: New Findings on Neoadjuvant Trastuzumab Deruxtecan and Anastrozole in Early-Stage Breast Cancer

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase II results from the TRIO-US B-12 TALENT study, which showed that patients with localized, hormone receptor–positive, HER2-low breast cancer who are treated with fam-trastuzumab...

breast cancer
immunotherapy

Sara A. Hurvitz, MD, on Updated Survival Results on T-DXd vs T-DM1 in Metastatic Breast Cancer

Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses phase III findings from the DESTINY-Breast03 study, which showed that second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to longer overall survival compared with...

breast cancer

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer

Ruth O’Regan, MD, of the University of Rochester Medical Center, discusses the Breast Cancer Index (BCI), a genomic assay that can assess the risk of late distant recurrence (5–10 years after diagnosis) of hormone receptor–positive, early-stage breast cancer. Among premenopausal women with this...

breast cancer

Yara Abdou, MD, on Race and Clinical Outcomes in the RxPONDER Breast Cancer Trial

Yara Abdou, MD, of the University of North Carolina, discusses results from the RxPONDER SWOG S1007 study, which showed that non-Hispanic Black women with hormone receptor–positive/HER2-negative breast cancer with one to three involved lymph nodes and a recurrence score of ≤ 25 have worse outcomes...

breast cancer
immunotherapy

T-DXd Yields Superior Outcomes Over Chemotherapy-Based Regimens in Patients Previously Treated With T-DM1: DESTINY-Breast02

Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1), according to results from ...

ASTRO Celebrates Contributions to Radiation Oncology With 2022 Gold Medals and Other Awards

The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2022 Gold Medal awards and other high-profile honors during an awards ceremony at the 2022 ASTRO Annual Meeting in San Antonio. ASTRO Gold Medal Wendell R. Lutz, PhD, and Tim R. Williams, MD, FASTRO, were awarded...

gynecologic cancers

ASTRO Issues Updated Guideline on Radiation Therapy for Patients With Endometrial Cancer

The American Society for Radiation Oncology (ASTRO) provided recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer, according to a newly updated clinical guideline published by Harkenrider et al in Practical Radiation Oncology....

T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03

Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial...

breast cancer
immunotherapy

Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer

Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...

issues in oncology

Cancer Drugs and Price Controls: Is It Time?

According to a recent article published in Cancer Epidemiology, Biomarkers & Prevention, cancer care in the United States exceeded $208 billion in 2020 and is expected to surpass $240 billion by 2030.1 These estimates are driven largely by a growing and aging population. The expenditures...

pancreatic cancer

How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease

The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...

breast cancer

First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer

In patients with hormone receptor–positive, HER2-negative advanced breast cancer—including patients with visceral crises—those treated with ribociclib plus endocrine therapy had fewer adverse events and significantly longer progression-free survival compared to those treated with combination...

breast cancer
lymphoma

Breast Implants After Mastectomy Associated With Very Low Risk of ALCL

The incidence of anaplastic large cell lymphoma (ALCL) has surged in recent years—possibly because of the growing use of textured breast implants. Considering this trend, some patients with breast cancer who undergo mastectomy may wonder if the benefits of getting reconstructive implants are worth...

kidney cancer
immunotherapy

Sumanta Pal, MD, on Renal Cell Carcinoma: CRISPR-Engineered CAR T Cells in Advanced Disease

Sumanta Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase I results from the COBALT-RCC study, a first-in-human clinical trial exploring CD70 CAR T-cell therapy in patients with clear cell renal cell carcinoma. The agent appeared to show an excellent safety profile with no...

breast cancer

Study Finds Racial Disparity in Prometastatic Tumor Microenvironment Among Patients With Residual Breast Cancer After Neoadjuvant Chemotherapy

Residual tumors from Black patients with estrogen receptor–positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy had a higher risk score associated with a biomarker of distant metastatic recurrence compared with tumors from White patients, according to new findings...

breast cancer

Genomic Assay May Predict Long-Term Prognosis in Premenopausal Patients With Hormone Receptor–Positive Early-Stage Breast Cancer

Among premenopausal patients with hormone receptor–positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on the Breast Cancer Index genomic assay had an increased risk of distant recurrence—and those with a low score on the Breast Cancer Index may have benefited...

breast cancer

Black Patients With Breast Cancer May Have Worse Outcomes Than Other Patients Despite Similar Genetic Recurrence Scores

Non-Hispanic Black patients with lymph node–positive, hormone receptor (HR)–positive/HER2-negative breast cancer experienced worse outcomes compared with the outcomes of non-Hispanic White, Asian, and Hispanic patients—despite similar 21-gene recurrence scores—according to new findings presented by ...

skin cancer
immunotherapy

Adjuvant Pembrolizumab May Improve Quality of Life in Patients With High-Risk Resected Melanoma

Taken together with the primary clinical results, a secondary analysis of the phase III SWOG S1404 randomized clinical trial demonstrated that pembrolizumab provides superior clinical and patient-reported quality-of-life outcomes compared to standard of care with adjuvant ipilimumab or high-dose...

prostate cancer

Lu-177 Vipivotide Tetraxetan Shows Benefit in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. The therapy demonstrated a statistically significant and clinically meaningful...

bladder cancer
immunotherapy

Roger Li, MD, on Bladder Cancer: Boosting Immune Checkpoint Blockade With an Oncolytic Adenovirus

Roger Li, MD, of the H. Lee Moffitt Cancer Center, discusses results from a phase II single-arm study of CG0070, a cancer-selective oncolytic adenovirus that creates mechanistic synergy with immune checkpoint blockade. In this trial, the virus was combined with pembrolizumab in patients with...

leukemia
genomics/genetics

FDA Approves Olutasidenib for Relapsed or Refractory AML With a Susceptible IDH1 Mutation

On December 1, the U.S. Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. The FDA also approved the Abbott RealTime IDH1...

issues in oncology

Risk of Cancer May Double for Patients With ‘Skewed’ Blood Cells

New research has shed light on how skewed X chromosome inactivation may be linked to the development of cancer and cardiovascular disease, according to a novel study published by Roberts et al in eLife. Background Because the X chromosome has so many more genes than the Y chromosome, in every cell...

gynecologic cancers

Are Patients Older Than 65 Years Being Overscreened for Cervical Cancer?

Patients older than 65 years may be undergoing unnecessary cervical cancer screenings, and more public health data may be needed on the utilization of cervical cancer screening–associated services among older patients to prevent potential harm and unnecessary costs, according to a new study...

breast cancer
cost of care

High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram

Twenty percent of patients are likely to forgo additional testing after an abnormal finding on a screening mammogram if there is a deductible, according to new findings presented at the Radiological Society of North America (RSNA) 2022 Annual Meeting. Background As health-care costs and insurance...

lung cancer

Lung Cancer Screening May Increase Long-Term Survival Rate

Diagnosing early-stage lung cancer using low-dose computed tomography (CT) screenings may improve patients’ long-term survival rate, according to long-term findings from the International Early Lung Cancer Action Program presented at the Radiological Society of North America (RSNA) 2022 Annual...

issues in oncology

Study Finds Americans Have a Low Awareness of the Link Between Alcohol Use and Increased Cancer Risk

Research shows that all beverage types containing ethanol, including wine, beer, and hard liquor, increase cancer risk, and that the risk increases with higher alcohol consumption. Even light drinking—no more than one drink per day—increases the risk for some cancers, including esophageal and...

hepatobiliary cancer

Novel DELFI AI Blood Test May Aid in Detecting Hepatocellular Carcinoma

A novel artificial intelligence (AI) blood testing technology—known as DELFI (DNA evaluation of fragments for early interception)—may successfully detect more than 80% of hepatocellular carcinomas, according to a new study published by Foda et al in Cancer Discovery. The findings were also...

lymphoma

Novel Research Suggests New Way to Target Mantle Cell Lymphoma Using FOXO1 Inhibitors

Preclinical research has shown that mantle cell lymphoma is so critically dependent on the FOXO1 protein that by blocking its activity with an experimental drug, the cancer’s growth may be slowed, according to a new study published by Jang et al in the Journal of Clinical Investigation....

Advertisement

Advertisement



Advertisement